Many clinicians are experiencing consumer resistance to
replacement therapy which has been manufacturedfrom mare's urine). In this paper I consider the ethical implications ofprescribing these preparations. I decide that patients should have a right to refuse such treatment but also ask whether a prescribing doctor should choose one preparation over another on moral grounds.
I determine that there is prima facie evidence to suggest that mares may suffer and that prescription of equine HRT (instead of synthetic oestrogen -oestriol) would therefore have to be justified in terms of either offering greater benefits to the women or offering greater value for money to the health service. Ifind that there is no substantial evidence to suggest that equine HRT offers unique advantages over and above oestriol. I conclude that it would be preferable for a doctor to recommend the synthetic oestrogen to women who want relieffrom the symptoms of the menopause and protection from osteoporosis and cardiovascular disease.
It is unusual for doctors to come across consumer resistance to a drug on ethical grounds; this form of protest is usually confined to such commodities as cosmetics produced by companies which test their products on animals or petrol produced by companies with suspect environmental credentials. Over the past year, however, some GPs and gynaecologists have recommended hormone replacement therapy (HRT) to their patients, only to be confronted by a refusal to accept those products which are derived from pregnant mare's urine.
Whilst this refusal can be seen as a perfectly proper exercise of a woman's autonomy, the doctor is faced with the moral issue of whether it is right to prescribe HRT derived from mare's urine to any of his or her other patients when there is an alternative available which is derived from plants.
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Are the mares harmed?
The first question I propose to ask is whether or not the mares are harmed in the production of equine HRT Is there any benefit arising out of using equine HRT which might outweigh any suffering to mares?
There seems to be little doubt that women benefit from HRT. They benefit from the reduction or elimination of unpleasant menopausal symptoms such as hot flushes and night sweats. They benefit from the reduced cardiovascular risks resulting from favourable changes in their serum lipids.9 They also benefit from the prevention of osteoporotic bone loss and their reduced risk of bone fractures as they get older. But all these benefits can also be obtained from HRT derived from plants and from processes that do not require any animal suffering.
In order to justify the use of equine HRT, I would have to be able to show that it offered considerable advantages over plant-derived HRT. Conversely if I was able to demonstrate that both forms of HRT were equally effective in each of the three areas above, I would be able to conclude that there is no difference which could outweigh any animal suffering.
Oestriol valerate is produced from soya beans. Once taken, it is degraded in the walls of the gut to release free oestradiol, this is the hormone which it is meant to replace. In this regard, oestriol is a very natural substance. Conjugated equine oestrogens are a mixture of many oestrogens of uncertain origins. The major constituents are oestrone sulphate and equilin. 10 The latter has a very long half life.
Effects on menopausal symptoms I have only the observations of my own practice to go on but I have found that my patients have been just as satisfied with the reduction of their menopausal symptoms when using plant-based oestrogen as they have been with equine oestrogen when I have switched them over. I appreciate that this exercise was in no way a double blind randomised control trial -but clearly the plant-based product has satisfied the licensing authorities that it is suitable for prescription as hormone replacement therapy.
Effects on the cardiovascular system There seems to be little doubt that HRT is associated with a decreased risk of cardiovascular disease in post-menopausal women. This seems to be because of a beneficial effects on serum lipids.'0 It is considered that all HRT preparations have cardioprotective effects but to date there have been no large-scale studies comparing the incidence of cardiovascular disease in populations using different HRT preparations. It has been shown however that oestriol (that is plant-derived HRT) significantly changes the serum lipids in post-menopausal women in a beneficial way (by decreasing the LDIJHDL ratio). 12 13 Bone metabolism
There is some doubt as to whether the minimum dose of conjugated equine oestrogen (0625 mg) is equivalent to the minimum dose of oestriol in preventing osteoporosis.'4 It is thought, however, that the higher 2 mg dose of oestriol is suitable for the long term prevention of osteoporosis. Two studies have shown that oestriol is effective at stopping the demineralisation of bone. '5 16 In the second study (Holland et al) the author commented in the discussion that the percentage increases in bone density with oestriol are greater than those with conjugated oestrogen 0-625 mg.
It seems that in these important areas, plantderived HRT seems to be at least as effective as equine HRT. Wyeth itself admits in a personal communication that "Studies on the pharmacodynamics of piperizine ostrone sulphate, micronised oestradiol and conjugated oestrogens indicate equivalent effects on hormonal systems at appropriate doses. Effects on suppression of menopausal symptoms and on prophylaxis of osteoporosis are likely to be equivalent".2 The letter then goes on to point out that conjugated oestrogens have been around longer than plant-derived oestrogens and so there is not equivalent long term data on cardiovascular risks.
It seems then that the only area in which there may be a claim for equine oestrogen to have superior efficacy is in cardiovascular effects. This is because the plant-derived HRT has not been around for long enough. There seems no reason to doubt that in the long term it is very unlikely that the cardiovascular results of using equine HRT will be found to be any better than those of using plantderived HRT.
Cost
If there were a significant cost-saving in prescribing equine HRT instead of oestriol then this might weigh in favour of using it despite there being some animal suffering involved. This is because those savings could be used elsewhere in the health service to decrease other forms of human suffering.
Comparing the costs of the various preparations is complicated by the fact that whilst low dose oestriol is sometimes adequate to control hot flushes and night sweats, the higher dose is recommended for the prevention of osteoporosis. The manufacturer of oestriol in the form of Progynova seems to have recognised this by charging the same for the 1 mg tabs as the 2 mg tabs. This contrasts with the equine oestrogen Premarin, which costs more if the higher dose is prescribed.
If I confine myself to basic preparations of HRT -(more costly forms of HRT exist for both types of hormone): If we look at the minimum doses needed to prevent osteoporosis then the equine oestrogen costs I lp a month less. If, however, the higher dose of Premarin has to be prescribed to relieve the woman's menopausal symptoms then the cost rises to 69p a month more. In view of this, I do not think that cost can be regarded as a significant factor in my calculations.
Utilitarian calculations
It is well known that there are problems with making utilitarian calculations such as deciding which "good" should be maximised (for instance, if we are to maximise welfare, should we only talk about the welfare of people?) There is also the difficulty of making objective calculations about what are often subjective assessments, for example, the amount of suffering that an animal undergoes. Having said this, I do not think there is a strong case to be made for prescribing equine HRT because of the specific benefits it gives women over and above plant-derived HRT. Plant-derived HRT is an effective alternative and although it seems that the higher dose must be given to ensure that the woman gains protection from osteoporosis, it has not been suggested that this higher level is harmful in anyway.
Since it is at least possible that some degree of animal suffering takes place in the production of equine HRT, then the onus is on the manufacturers to prove that some extra benefit to menopausal women or a wider population can be derived from the use of equine HRT. I believe that I have established that the plant-derived alternative is of equal mare's urine? efficacy to equine HRT and is of comparable cost. My conclusion is that a utilitarian analysis would guide a doctor away from recommending equine HRT to his or her patients.
Other moral considerations
A utilitarian analysis has appeal to a pragmatic working doctor such as myself. I accept, however, that it is not the only way in which people may look at the moral issues concerning the use of equine HRT. From the perspective of enhancing a patient's autonomy (which also appeals to me greatly) it could be argued that the patient who is prescribed equine HRT without having the issues explained to her is being denied a chance to exercise her full autonomy. If we look at the same thing from the standpoint of informed consent, I could ask whether a woman's consent to take HRT is free and informed if she is not told about its mode of production. There are some women who arrive in our consulting rooms having already decided that they would not The British Medical Association has recently established a multi-professional steering group to examine the ethical implications of new genetic technology and to provide practical guidance for health professionals wbo are not specialists in genetics but who are increasingly asked to advise on the implications of this technology.
The steering group is anxious to gather as much information as possible on current practice and the practical ethical problems which arise, from health professionals, counsellors, social workers and lawyers. The group would welcome evidence of good practice and unresolved issues from any of these sources or from others who have experience of these issues.
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